AstraZeneca gets first approval for drug in type 1 diabetes

25 March 2019

AstraZeneca’s (LSE: AZN) Forxiga (dapagliflozin) has become the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes.

The Anglo-Swedish pharma major has at the same time scored its first approval in type 1 diabetes with the European Commission’s decision to green-light Forxiga as adjunct to insulin in patients with a BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycemic control despite optimal insulin therapy.

Data from the Phase III DEPICT trial formed the basis of this approval for Forxiga, which is currently under regulatory review in Japan and the USA for use as an adjunct treatment to insulin in adults with type 1 diabetes, with a decision expected in the first and second half of 2019, respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK